Press releases
10 March 2021, Zwingenberg, Germany

Resolutions of the Annual General Meeting for the Fiscal Year 2019/2020 of BRAIN AG

  • Executive Board and Supervisory Board approved by a qualified majority
  • Shareholders vote for change of company name to BRAIN Biotech AG
  • Shareholder majority approves capital anticipatory resolutions

At today's Annual General Meeting of B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG), the discharge of the Executive Board and Supervisory Board was approved by a large majority. All of the Annual General Meeting resolutions were passed by the shareholders, including the application for conditional and authorized capital as well as the change of the company name to BRAIN Biotech AG.

Since its foundation 28 years ago, BRAIN has evolved from a research-driven and network-oriented biotech startup into a production-oriented, integrated company with a strong scientific foundation. In the future, this development will also be reflected in the name.

Chief Executive Officer Adriaan Moelker summarizes the positive developments as: „We focused our development pipeline on seven promising R&D programs; together with our partner Roquette we have transferred our protein sweetener Brazzein to the commercialization phase; we purchased the outstanding minority stake of WeissBioTech; and we have again invested in the promising enzymatic wound-cleaning program as part of our SolasCure shareholding. Last but not least, our effective crisis management of the Covid 19 pandemic and forward-looking actions with regard to the Brexit also contributed to a successful fiscal year.”

Chief Financial Officer Lukas Linnig had presented the financial figures for the past fiscal year and said: “During the Corona pandemic, BRAIN's overall core business has proven to be sustainable. We are now working continuously to further develop the structure of the BRAIN Group and are investing significantly in our own research and development as well as in our future products.”

The shareholders' meeting elected three candidates to the Supervisory Board, including Professor Dr.-Ing. Wiltrud Treffenfeldt and Stephen Catling, both of whom had been members of the Supervisory Board on the basis of a court appointment since October 14, 2020 until this shareholders' meeting. Dr. Anna Carina Eichhorn, a member of the Supervisory Board since 2017 and currently Deputy Chairwoman, was re-elected to the Board by the shareholders' meeting.

The Chairman of the Supervisory Board, Dr. Georg Kellinghusen, who chaired the Annual General Meeting, was very satisfied with the developments in the past financial year: “Following some significant management changes, BRAIN has now restored management continuity. The company has made good progress in the past year in developing itself in regards to business, organization and strategy. The company is well positioned to achieve its medium-term goals."

At the time of voting on the agenda items, between 11,367,594 and 13,505,974 of the capital stock divided into 19,861,360 registered shares were represented. The participation rate in voting, measured against the capital stock, was hence between 57.23% and 68.00%.

The detailed voting results as well as the presentation of the Management Board and all other documents relating to the Annual General Meeting are available on the BRAIN AG website at https://www.brain-biotech.com/investors/annual-general-meetings/agm-fy-2019-20


BRAIN AGM 2021 virtual event
© BRAIN AG

Press Image

Chairman of the Supervisory Board Dr. Georg Kellinghusen, CEO Adriaan Moelker and CFO Lukas Linnig (from left to right) during the digital Annual General Meeting for fiscal year 2019/20

About BRAIN

BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).

Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.

For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Share this page